immatics biotechnologies GmbH – Product Pipeline Review

Global Markets Direct’s, ‘immatics biotechnologies GmbH – Product Pipeline Review – 2016’, provides an overview of the immatics biotechnologies GmbH’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by immatics biotechnologies GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of immatics biotechnologies GmbH

The report provides overview of immatics biotechnologies GmbH including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses immatics biotechnologies GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features immatics biotechnologies GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate immatics biotechnologies GmbH’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for immatics biotechnologies GmbH

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding immatics biotechnologies GmbH’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Immatics Biotechnologies GmbH Snapshot 6

Immatics Biotechnologies GmbH Overview 6

Key Information 6

Key Facts 6

Immatics Biotechnologies GmbH - Research and Development Overview 7

Key Therapeutic Areas 7

Immatics Biotechnologies GmbH - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Pipeline Products - Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

Immatics Biotechnologies GmbH - Pipeline Products Glance 15

Immatics Biotechnologies GmbH - Late Stage Pipeline Products 15

Phase III Products/Combination Treatment Modalities 15

Immatics Biotechnologies GmbH - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Immatics Biotechnologies GmbH - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Immatics Biotechnologies GmbH - Drug Profiles 20

IMA-901 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

IMA-910 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

APVAC-1 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

APVAC-2 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

IMA-950 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

IMA-101 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

IMA-102 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

IMA-201 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

IMA-202 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

IMA-203 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

IMA-300 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

IMA-301 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Recombinant Protein for Solid Tumors 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Immatics Biotechnologies GmbH - Pipeline Analysis 38

Immatics Biotechnologies GmbH - Pipeline Products by Target 38

Immatics Biotechnologies GmbH - Pipeline Products by Route of Administration 39

Immatics Biotechnologies GmbH - Pipeline Products by Molecule Type 40

Immatics Biotechnologies GmbH - Recent Pipeline Updates 41

Immatics Biotechnologies GmbH - Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Appendix 45

Methodology 45

Coverage 45

Secondary Research 45

Primary Research 45

Expert Panel Validation 45

Contact Us 45

Disclaimer 46

List of Tables

List of Tables

Immatics Biotechnologies GmbH, Key Information 6

Immatics Biotechnologies GmbH, Key Facts 6

Immatics Biotechnologies GmbH – Pipeline by Indication, 2016 8

Immatics Biotechnologies GmbH – Pipeline by Stage of Development, 2016 9

Immatics Biotechnologies GmbH – Monotherapy Products in Pipeline, 2016 10

Immatics Biotechnologies GmbH – Partnered Products in Pipeline, 2016 11

Immatics Biotechnologies GmbH – Partnered Products/ Combination Treatment Modalities, 2016 12

Immatics Biotechnologies GmbH – Out-Licensed Products in Pipeline, 2016 13

Immatics Biotechnologies GmbH – Out-Licensed Products/ Combination Treatment Modalities, 2016 14

Immatics Biotechnologies GmbH – Phase III, 2016 15

Immatics Biotechnologies GmbH – Phase II, 2016 16

Immatics Biotechnologies GmbH – Phase I, 2016 17

Immatics Biotechnologies GmbH – Preclinical, 2016 18

Immatics Biotechnologies GmbH – Discovery, 2016 19

Immatics Biotechnologies GmbH – Pipeline by Target, 2016 38

Immatics Biotechnologies GmbH – Pipeline by Route of Administration, 2016 39

Immatics Biotechnologies GmbH – Pipeline by Molecule Type, 2016 40

Immatics Biotechnologies GmbH – Recent Pipeline Updates, 2016 41

Immatics Biotechnologies GmbH, Subsidiaries 44

List of Figures

List of Figures

Immatics Biotechnologies GmbH – Pipeline by Indication, 2016 8

Immatics Biotechnologies GmbH – Pipeline by Stage of Development, 2016 9

Immatics Biotechnologies GmbH – Monotherapy Products in Pipeline, 2016 10

Immatics Biotechnologies GmbH – Pipeline by Route of Administration, 2016 39

Immatics Biotechnologies GmbH – Pipeline by Molecule Type, 2016 40

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports